Frist hails vaccine makers' protections

16 January 2006

US Senate Majority Leader Bill Frist has welcomed provisions within the fiscal 2006 Department of Defense Conference Report, approved by the Senate just before Christmas, which contains certain protections for manufacturers of vaccines to be used in the event of health emergencies and pandemics.

Real, imminent dangers posed by diseases like avian flu underscore the serious need to bolster US preparedness by enacting meaningful liability reform, said Sen Frist, adding that the limited protections extended by the Public Readiness and Emergency Preparedness Act contained within the Report will allow life-saving countermeasures such as an H5N1 avian flu vaccine to be developed, deployed and administered.

"These sensible and measured reforms will encourage manufacturers, distributors and first responders to keep Americans safe once disaster strikes. The bill strikes a reasonable balance where those who are harmed will be fairly compensated and life-saving products will be available in ample supply to protect and treat as many Americans as possible," said the Senate Majority Leader.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight